Peritoneal cancer — the dissemination of malignant cells throughout the peritoneal cavity from primary peritoneal mesothelioma, pseudomyxoma peritonei, ovarian cancer, colorectal cancer, gastric cancer, and appendiceal malignancy, characterized by carcinomatosis, ascites, and bowel obstruction — creating the most surgically-intensive segment in gastrointestinal and gynecologic oncology, with the Peritoneal Cancer Market reflecting cytoreductive surgery with hyperthermic intraperitoneal chemotherapy and pressurized intraperitoneal aerosol chemotherapy as the premium locoregional commercial drivers.

CRS-HIPEC standardization and patient selection — the cytoreductive surgery achieving complete macroscopic tumor removal (CC-0/1) combined with hyperthermic intraperitoneal chemotherapy (mitomycin C, oxaliplatin, cisplatin, doxorubicin at 41-43°C for 60-90 minutes) demonstrating median overall survival of forty to sixty months in appendiceal pseudomyxoma peritonei and twenty-two to forty months in colorectal peritoneal metastases creating the procedure-standardization commercial foundation. The Peritoneal Surface Oncology Group International (PSOGI) consensus on patient selection (PCI <20, good performance status, absence of extra-abdominal disease) and completeness of cytoreduction scoring enabling outcome prediction and center accreditation, with approximately 2,500-3,500 CRS-HIPEC procedures performed annually in the US at fifty to sixty specialized centers.

PIPAC and pressurized intraperitoneal aerosol chemotherapy — the laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin delivering chemotherapy as an aerosol under 12 mmHg pressure achieving deeper tissue penetration (0.5-1.0 mm versus 0.1-0.3 mm HIPEC) creating the minimally invasive commercial alternative. PIPAC demonstrating objective response rates of sixty to seventy percent in heavily pretreated ovarian and gastric peritoneal metastases with repeatability every 6-8 weeks, while the PIPAC-OV2 and PIPAC-GA2 trials investigating PIPAC as consolidation after systemic chemotherapy with potential for outpatient administration reducing morbidity compared to open CRS-HIPEC.

Systemic therapy integration and targeted agents — the FOLFOXIRI, FOLFIRINOX, and triplet chemotherapy regimens combined with anti-VEGF (bevacizumab) and anti-EGFR (cetuximab, panitumumab) for colorectal peritoneal metastases, and PARP inhibitors (olaparib, niraparib) and anti-angiogenics for ovarian peritoneal carcinomatosis creating the systemic-locoregional combination commercial evolution. Neoadjuvant systemic therapy achieving conversion of initially unresectable peritoneal disease in fifteen to twenty-five percent of colorectal patients, while HIPEC with oxaliplatin (30-minute, 460 mg/m²) combined with perioperative FOLFOX demonstrating superior survival compared to systemic therapy alone in PRODIGE-7 trial (though not reaching statistical significance for overall survival).

Novel intraperitoneal drug delivery and immunotherapy — the intraperitoneal catumaxomab (anti-EpCAM x anti-CD3 trifunctional antibody) for malignant ascites, intraperitoneal CAR-T cell therapy, and immune checkpoint inhibitor intraperitoneal administration creating the innovation commercial frontier. Intraperitoneal pembrolizumab and nivolumab demonstrating enhanced peritoneal cavity drug exposure with reduced systemic toxicity in early-phase trials, while tumor-infiltrating lymphocyte (TIL) therapy and mesothelin-targeted CAR-T for peritoneal mesothelioma under investigation with potential for curative-intent locoregional immunotherapy.

Do you think PIPAC will eventually replace open CRS-HIPEC as the standard intraperitoneal chemotherapy delivery method, or will the established survival data, complete cytoreduction capability, and HIPEC's deeper tissue penetration sustain open surgical approach dominance?

What are the treatment modalities and outcomes for peritoneal cancer by primary site? Appendiceal/PMP: CRS-HIPEC (CC-0/1): median OS 60-100 months; 10-year survival 60-70%; optimal; Colorectal: CRS-HIPEC + systemic: median OS 30-40 months; 5-year survival 25-35%; neoadjuvant FOLFOXIRI + bevacizumab improving resectability; Ovarian: CRS + HIPEC (interval or primary): median OS 60-80 months; PIPAC consolidation; PARP maintenance; Gastric: CRS-HIPEC (selective): median OS 15-25 months; PIPAC + systemic under investigation; Peritoneal mesothelioma: CRS-HIPEC: median OS 40-60 months; 5-year survival 30-50%; best results of all peritoneal malignancies; HIPEC agents: mitomycin C (appendiceal, mesothelioma, 30-40 mg/m²); oxaliplatin (colorectal, 460 mg/m², 30 min); cisplatin + doxorubicin (ovarian, mesothelioma); PIPAC: cisplatin 7.5 mg/m² + doxorubicin 1.5 mg/m²; Patient selection: PCI <20 (optimal <12); ECOG 0-1; no extra-abdominal disease; adequate organ function; experienced center (>20 cases/year).

What is the market size and center distribution for peritoneal cancer treatment? Market structure: global peritoneal cancer treatment market approximately $2.5-3.5 billion (2024); growth rate 9-12% CAGR; segmentation: CRS-HIPEC procedures 40-45%, systemic therapy 30-35%, PIPAC 8-10%, supportive care/palliative 10-15%; geographic: US 35%, Europe 30%, Asia-Pacific 20%, ROW 15%; procedure volume: CRS-HIPEC 8,000-12,000 globally per year; US 2,500-3,500; specialized centers: US 50-60; Europe 80-100; pricing: CRS-HIPEC $80,000-150,000; PIPAC $15,000-25,000 per session; systemic therapy $50,000-100,000/year; key centers: MD Anderson, Wake Forest, Washington Cancer Institute, Netherlands Cancer Institute, Gustave Roussy, Basingstoke; key players: surgical oncology centers; device: ThermaSolutions (HIPEC perfusion); RanD (PIPAC device); chemotherapy: standard oncology agents; emerging: intraperitoneal immunotherapy developers; drivers: PSOGI standardization, outcome data maturation, PIPAC adoption, ovarian HIPEC acceptance, patient referral centralization; challenges: procedure morbidity (30-40% grade 3-4), mortality (1-3%), center volume-outcome relationship, cost-effectiveness debate, workforce training.

#PeritonealCancer #CRSHIPEC #PIPAC #PeritonealSurfaceOncology #PseudomyxomaPeritonei #OvarianCancer #IntraperitonealChemotherapy #PSOGI